Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have provided significant visual and anatomic improvements for patients with retinal diseases. For those patients who do not respond optimally to anti-VEGF therapies, targeting of alternative pathways involved in abnormal angiogenesis and increased vascular permeability may be beneficial. One such target is the angiopoietin/Tie2 pathway, with promising novel agents currently being assessed in clinical studies.
In this continuing medical education activity, experts in the field examine how angiopoietins regulate vascular stability under normal conditions and drive vascular instability in retinal and choroidal vascular diseases. They also evaluate the clinical data for emerging injectable therapies that act on the angiopoietin/Tie2 pathway to potentially improve visual outcomes.